⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IONS News
Ionis Pharmaceuticals, Inc. Common Stock
Migraine Clinical Trial Pipeline Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight
globenewswire.com
LUN
LLY
AMGN
NVS
TEVA
ALLER
BHVN
DRREDDY
ABBV
IMPL
ZSAN
AXSM
AEON
IONS
CHRC
AZN
GSK
WSTN
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
businesswire.com
IONS
Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Complement Inhibitor Therapies | DelveInsight
globenewswire.com
JNJ
OCGN
APLS
ALXN
IONS
BLTE
LCTX
REGN
AVNX
NBIX
STE
COG
AVD
OCUGEN
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
businesswire.com
IONS
Familial Chylomicronemia Syndrome Global Market Analysis and Forecast, 2025-2035: Healthcare Access and Education Enhance FCS Market Expansion
globenewswire.com
IONS
ARWR
ABT
KLKB1 Inhibitors Market to Reach New Heights by 2034 Owing to the Launch of Novel Therapies | DelveInsight
prnewswire.com
NTLA
ASTX
RZLT
IONS
KALV
BCRX
TAK
KAVL
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
globenewswire.com
BIIB
IONS
Biogen Completes Acquisition of Alcyone Therapeutics
globenewswire.com
BIIB
IONS
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
businesswire.com
IONS
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
businesswire.com
IONS